<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01107106</url>
  </required_header>
  <id_info>
    <org_study_id>2914-010</org_study_id>
    <secondary_id>2009-017771-21</secondary_id>
    <nct_id>NCT01107106</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Women</brief_title>
  <official_title>Prospective Observational Single Arm Open-Label Multicenter Study to Assess the Safety, Tolerability and Efficacy of ellaOne® (Ulipristal Acetate) for Emergency Contraception in Postmenarcheal Adolescent Girls and Adult Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HRA Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HRA Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this observational study is to assess the safety and tolerability of ellaOne®
      in routine conditions of use for emergency contraception in postmenarcheal adolescents and
      adult women who want to prevent pregnancy up to 5 days after unprotected sexual intercourse.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency of adverse events after ellaOne® intake in routine conditions of use for emergency contraception</measure>
    <time_frame>Two months (i.e. all along 2 menstrual cycles following ellaOne® intake)</time_frame>
    <description>Collection of adverse events, concomitant treatments, length of menstrual cycle, and vaginal bleeding/spotting through follow-up contacts and a diary completed by the patient</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pregnancy rate observed after taking ellaOne® in routine conditions of use for emergency contraception</measure>
    <time_frame>Two months (i.e. during two menstrual cycles following ellaOne® intake)</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">579</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Adolescents</arm_group_label>
    <description>250 postmenarcheal adolescent girls</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adults</arm_group_label>
    <description>250 adult women</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ellaOne® (ulipristal acetate)</intervention_name>
    <description>one single oral dose (30 mg tablet)</description>
    <arm_group_label>Adolescents</arm_group_label>
    <other_name>ellaOne®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ellaOne® (ulipristal acetate)</intervention_name>
    <description>one single oral dose (30 mg tablet)</description>
    <arm_group_label>Adults</arm_group_label>
    <other_name>ellaOne®</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adolescents and adult women seeking emergency contraception in family planning centers and
        youth clinics in Sweden
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Having received ellaOne® as emergency contraception at the clinical site

          -  Postmenarcheal adolescents or adult women

          -  Willing to provide information on bleeding, sexual intercourses, method of
             contraception, concomitant medications and adverse events for the next two menstrual
             periods and to complete the diary accordingly

          -  Willing to provide information on pregnancy outcome / delivery and newborn's health at
             delivery

          -  Able to provide written informed consent

          -  Willing to not participate in a clinical trial before the end of study participation

        Exclusion Criteria:

          -  Currently participating in any interventional clinical trial (testing an
             Investigational Medicinal Product)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPRM Central clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>CO 80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PPRM Southwest clinic</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>CO 80232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elizabeth Blackwell Health Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>PA 19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Locust Health Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>PA19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dept of Women &amp; Child Health - Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brook clinic</name>
      <address>
        <city>Belfast</city>
        <zip>BT12DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2010</study_first_submitted>
  <study_first_submitted_qc>April 19, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2010</study_first_posted>
  <last_update_submitted>May 14, 2013</last_update_submitted>
  <last_update_submitted_qc>May 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Contraceptive Methods</keyword>
  <keyword>Female Contraception</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emergencies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

